Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vimseltinib and Avelumab in Advanced High-grade Sarcoma
NCT04242238Phase 1Completed
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Jan 2020
- Primary completion
- Aug 2025
- Modality
- Fragment-Derived Small Molecules, Reversible Covalent Inhibitors, Bivalent/Multivalent Binders
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of vimseltinib in sarcoma, leiomyosarcoma (LMS), undifferentiated pleomorphic sarcoma (UPS) and 2 more, sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoints: Maximum tolerated dose at 1 year and Overall Response Rate at 48 weeks. Started Jan 2020; status: completed.
02
Drugs
vimseltinib
03
Conditions
sarcomaleiomyosarcoma (LMS)undifferentiated pleomorphic sarcoma (UPS)myxofibrosarcoma (MFS)Liposarcoma
Beyond the preview
Go deeper on NCT04242238.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04242238.